Impaired Fibrinolytic Capacity in Patients with Inflammatory Bowel Disease

Abstract

SummaryThe venous occlusion test was applied to 17 patients with inflammatory bowel disease (IBD; 7 cases of Crohn’s disease, 10 cases of ulcerative colitis). Results were compared to those obtained in 20 healthy matched control subjects. Patients with IBD had significantly decreased t-PA Ag release (p <0.001) and had no significant vWF Ag release. Residual PAI activity was evidenced after venous stasis in the IBD group but not in the control group. Hypofibrinolysis was more important in patients with an evolutive IBD than in patients with IBD in remission. Impaired systemic fibrinolytic capacity might contribute to an increased risk for thromboembolic complications and to the pathogenesis of inflammatory bowel disease.

The Fibrinolytic System in the Hemolytic Uremic Syndrome: In Vivo and In Vitro Studies

“…However, it is well known that patients with kidney diseases respond less pronouncedly to DDAVP than healthy volunteers, and some are nonresponsive (46,47). Unresponsiveness of t-PA and vWF antigen release to DDAVP infusion has also been observed in patients with inflammatory bowel disease (Crohn's disease, ulcerative colitis) who have a normal level of t-PA and vWF before DDAVP infusion (48). It is therefore possible that the lack of response to DDAVP in HUS patients is caused by a simultaneous disturbance of the kidney and the intestine.…”

Long-term risk of mesenteric ischemia in patients with inflammatory bowel disease: a 13-year nationwide cohort study in an Asian population

“…[22][23][24][25] Evidence showed that patients with IBD may experience platelet activation, 26 altered coagulation, 27,28 and impaired fibrinolysis. 29 It is unclear whether coagulation imbalance contributes to the development of mesenteric ischemia in patients with IBD.…”

Plasma Thrombin-activatable Fibrinolysis Inhibitor Levels Correlate with the Disease Activity of Ulcerative Colitis

“…Although hyperfibrinolysis and hypofibrinolysis have been demonstrated in patients with UC and CD, the role of the fibrinolytic system in patients with IBD remains controversial (22,23). In this context, TAFI is an important inhibitor of this system, which cleaves the lysine binding sites of partially degraded fibrin, interfering with the interaction between plasminogen and fibrin (6).…”